Synergies between MK-1775 (WEE1 inhibitor) and MK-8776 (CHK inhibitor), and each with gemcitabine have been observed in tumor cells, including melanoma, colon cancer and p53 mutant pancreatic cancers [46–50]. The gene discussed is TP53; the disease is neoplasm.